Expert opinion on emerging drugs
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Clifton C Mo, Yuxin Liu, Omar Nadeem, Shonali Midha, Jacob P Laubach, Taya Jamal Salman, Taylor Nicholson, Kaleigh Donnelly, Giada Bianchi, Adam S Sperling, Monique A Hartley-Brown, Paul G Richardson
Published: 202510.1080/14728214.2025.2575570
Abstract
INTRODUCTION: The treatment armamentarium for multiple myeloma (MM) has evolved substantially over the past 20 years. Standard-of-care regimens for newly diagnosed MM and early relapsed/refractory disease (RRMM) include quadruplets and triplets compr…
Preview only. Read the full abstract at the source